View Item 

Show simple item record

First‐in‐Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection

dc.contributor.authorFlechner, S. M.en_US
dc.contributor.authorMulgoankar, S.en_US
dc.contributor.authorMelton, L. B.en_US
dc.contributor.authorWaid, T. H.en_US
dc.contributor.authorAgarwal, A.en_US
dc.contributor.authorMiller, S. D.en_US
dc.contributor.authorFokta, F.en_US
dc.contributor.authorGetts, M. T.en_US
dc.contributor.authorFrederick, T. J.en_US
dc.contributor.authorHerrman, J. J.en_US
dc.contributor.authorPuisis, J. P.en_US
dc.contributor.authorO'Toole, L.en_US
dc.contributor.authorSung, R.en_US
dc.contributor.authorShihab, F.en_US
dc.contributor.authorWiseman, A. C.en_US
dc.contributor.authorGetts, D. R.en_US
dc.date.accessioned2014-06-04T14:57:08Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-06-04T14:57:08Z
dc.date.issued2014-06en_US
dc.identifier.citationFlechner, S. M.; Mulgoankar, S.; Melton, L. B.; Waid, T. H.; Agarwal, A.; Miller, S. D.; Fokta, F.; Getts, M. T.; Frederick, T. J.; Herrman, J. J.; Puisis, J. P.; O'Toole, L.; Sung, R.; Shihab, F.; Wiseman, A. C.; Getts, D. R. (2014). "First‐in‐Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection." American Journal of Transplantation 14(6): 1346-1355.en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/107383
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherInductionen_US
dc.subject.otherAcute Rejectionen_US
dc.subject.otherKidney Transplantationen_US
dc.titleFirst‐in‐Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejectionen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/107383/1/ajt12698.pdf
dc.identifier.doi10.1111/ajt.12698en_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceSempe P, Bedossa P, Richard MF, Villa MC, Bach JF, Boitard C. Anti‐alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. Eur J Immunol 1991; 21: 1163 – 1169.en_US
dc.identifier.citedreferenceNankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451 – 1462.en_US
dc.identifier.citedreferenceDierselhuis M, Goulmy E. The relevance of minor histocompatibility antigens in solid organ transplantation. Curr Opin Organ Transplant 2009; 14: 419 – 425.en_US
dc.identifier.citedreferenceArchbold JK, Ely LK, Kjer‐Nielsen L, et al. T cell allorecognition and MHC restriction—A case of Jekyll and Hyde ? Mol Immunol 2008; 45: 583 – 598.en_US
dc.identifier.citedreferenceHalloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715 – 2729.en_US
dc.identifier.citedreferenceVincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770 – 781.en_US
dc.identifier.citedreferenceFlechner SM. Sirolimus in kidney transplantation indications and practical guidelines: De novo sirolimus based therapy without calcineurin inhibitors. Transplantation 2009; 87: S1 – S6.en_US
dc.identifier.citedreferenceWebster AC, Playforde G, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: A meta‐analysis of randomized trials. Transplantation 2004; 77: 166 – 176.en_US
dc.identifier.citedreferencePatlola V, Zhong X, Reed GW, Mandelbrot DA. Efficacy of anti‐IL‐2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant 2007; 7: 1832 – 1841.en_US
dc.identifier.citedreferenceCai J, Terasaki PI. Induction immunosuppression improves long‐term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511 – 1515.en_US
dc.identifier.citedreferenceNashan B. Antibody induction therapy in renal transplant patients receiving calcineurin‐inhibitor immunosuppressive regimens. Biodrugs 2005; 19: 39 – 46.en_US
dc.identifier.citedreferenceWagner SJ, Brennan DC. Induction therapy in renal transplant recipients: How convincing is the current evidence ? Drugs 2012; 72: 671 – 683.en_US
dc.identifier.citedreferenceBrennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967 – 1977.en_US
dc.identifier.citedreferenceHanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909 – 1919.en_US
dc.identifier.citedreferenceGuttmann RD, Caudrelier P, Alberici G, Touraine JL. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc 1997; 29: 24S – 26S.en_US
dc.identifier.citedreferenceBroeders N, Wissing KM, Crusiaux A, Kinnaert P, Vereerstraeten P, Abramowicz D. Mycophenolate mofetil, together with cyclosporin A, prevents anti‐OKT3 antibody response in kidney transplant recipients. J Am Soc Nephrol 1998; 9: 1521 – 1525.en_US
dc.identifier.citedreferenceKaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone‐free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction—Long‐term results. Am J Transplant 2005; 5: 2539 – 2548.en_US
dc.identifier.citedreferenceMatsumoto Y, Tsuchida M, Hanawa H, Abo T. Successful prevention and treatment of autoimmune encephalomyelitis by short‐term administration of anti‐T‐cell receptor alpha beta antibody. Immunology 1994; 81: 1 – 7.en_US
dc.identifier.citedreferenceKhariwala SS, Knott PD, Dan O, Klimczak A, Siemionow M, Strome M. Pulsed immunosuppression with everolimus and anti‐alphabeta T‐cell receptor: Laryngeal allograft preservation at six months. Ann Otol Rhinol Laryngol 2006; 115: 74 – 80.en_US
dc.identifier.citedreferenceSiemionow MZ, Izycki DM, Zielinski M. Donor‐specific tolerance in fully major histocompatibility major histocompatibility complex‐mismatched limb allograft transplants under an anti‐alphabeta T‐cell receptor monoclonal antibody and cyclosporine A protocol. Transplantation 2003; 76: 1662 – 1668.en_US
dc.identifier.citedreferenceWaid TH, Lucas BA, Thompson JS, et al. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: Final analysis of a phase II clinical trial. Transplantation 1997; 64: 274 – 281.en_US
dc.identifier.citedreferenceWaid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular rejection with T10B9.1A‐31 or OKT3 in renal allograft recipients. Transplantation 1992; 53: 80 – 86.en_US
dc.identifier.citedreferenceBeelen DW, Graeven U, Schulz G, et al. Treatment of acute graft‐versus‐host disease after HLA‐partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase‐I/II trial. Onkologie 1988; 11: 56 – 58.en_US
dc.identifier.citedreferenceHaynes BF, Fauci AS. The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus‐derived lymphocytes. J Clin Invest 1978; 61: 703 – 707.en_US
dc.identifier.citedreferenceGetts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD. Have we overestimated the benefit of human(ized) antibodies ? MAbs 2010; 2: 682 – 694.en_US
dc.identifier.citedreferenceFlechner SM, Goldfarb DA, Fairchild R, et al. A randomized prospective trial of low dose OKT3 to prevent rejection and minimize side effects in recipients of kidney transplants. Transplantation 2000; 69: 2374 – 2381.en_US
dc.identifier.citedreferenceNashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193 – 1198.en_US
dc.identifier.citedreferenceGetts DR, Shankar S, Chastain EM, et al. Current landscape for T‐cell targeting in autoimmunity and transplantation. Immunotherapy 2011; 3: 853 – 870.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajt12698.pdf
Size:
867.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.